← KO forward model

KO · Forward model · North America · Bear case

What has to happen in North America

Model as of

This page changes North America inside the complete KO model. Every other vertical, corporate programme and valuation assumption stays in the selected portfolio case.

KO forward model
Horizon
Consolidated fair value $59.38 all other verticals held in this portfolio case
Final-quarter revenue $6.19B 46% of company revenue
Explicit segment contribution $26.58B EBITDA less segment capex, before corporate items

The second half gives back what the calendar gave. Coca-Cola's own guidance implies a comparable revenue bridge of roughly +5 organic, +1 currency and -2 to -3 from acquisitions and divestitures; consensus turns that into FY2026 revenue of $49.72bn, which against first-half actuals of $25,852M leaves $23,868M for the second half - a 1.7% decline after a first half that grew 9.2%. Two disclosed mechanisms do it: six fewer days in 2026 Q4 than in 2025 Q4, and the African bottling deconsolidation. FY2027 consensus revenue of $49.82bn is 0.2% above FY2026, so the sell side does not expect the lost revenue back. This case takes the top of the derived $1.0-1.4bn African bottling range, trims the compounding growth of every line and marks the exit multiple down to 17x.

North America

Basis quarter$5.41B
Final quarter$6.19B
Implied CAGR+3%
Final revenue mix46%

The United States and Canada, the largest vertical at $5,405M of third-party revenue, 40.4% of the group, and the only geographic segment carrying material capital expenditure at 3.3% of its own revenue. In 2026 Q2 reported revenue grew 7% on concentrate sales +3 and price/mix +4, with no currency and no structural effect at all: the cleanest organic line in the company.

Last four quarters
2025 Q3 $5.25B Reported
2025 Q4 $4.94B Estimated
2026 Q1 $4.89B Reported
2026 Q2 $5.41B Reported
Concentrate sales to United States and Canadian bottlersFinished product operations including fairlife, BODYARMOR, Minute Maid and fountain syrupsMonster distribution coordination fees
Sequential growth +1.3%/qtr decaying toward +0.9% 1.31% is the 2024 Q2 to 2026 Q2 compound quarterly rate on the deseasonalised level.
North America

Latest: $6.19B (2031Q2E)

Period Value
2024Q1 $4.22B
2024Q2 $4.87B
2024Q3 $5.04B
2024Q4 $4.73B
2025Q1 $4.36B
2025Q2 $5.03B
2025Q3 $5.25B
2025Q4 $4.94B
2026Q1 $4.89B
2026Q2 $5.41B
2026Q3E $5.67B
2026Q4E $5.13B
2027Q1E $4.98B
2027Q2E $5.60B
2027Q3E $5.86B
2027Q4E $5.29B
2028Q1E $5.13B
2028Q2E $5.76B
2028Q3E $6.02B
2028Q4E $5.43B
2029Q1E $5.26B
2029Q2E $5.91B
2029Q3E $6.17B
2029Q4E $5.57B
2030Q1E $5.39B
2030Q2E $6.05B
2030Q3E $6.32B
2030Q4E $5.70B
2031Q1E $5.52B
2031Q2E $6.19B

Assumptions & reasoning

  • The cleanest seasonal shape in the group: amplitude 0.147 against a worst-case window-to-window spread of 0.013, roughly eleven times the noise, with the summer peak and the Q1 trough repeating in both windows.
  • The 2025 BodyArmor trademark impairment of $960M was attributed to a slowing projected long-term growth rate for the category and an intensifying competitive environment. That is a disclosed management markdown of one of this vertical's growth engines and it is not separately modelled here.
  • United States unit case volume is about 16% of worldwide volume against roughly 40% of revenue, so this line depends on price and mix holding rather than on cases.
KO model map

Explore another vertical